CHRS/MNTA/etc—USPTO denies CHRS’ IPR on ABBV’s ‘619 patent covering Humira formulation: https://finance.yahoo.com/news/coherus-biosciences-provides-619-ipr-155744747.html CHRS is -7%; MNTA is -2%; and ABBV is +6%. ABBV’s gain today is mostly due to positive phase-2b data for Upadacitinib (#msg-134452680).